Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

被引：75

作者：

Jung, Dong Sik ^{[1
,2
,3
,5
]}

Tverdek, Frank P. ^{[4
]}

Kontoyiannis, Dimitrios P. ^{[1
,2
,3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Infect Control, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Employee Hlth, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Pharm Clin Programs, Houston, TX 77030 USA

[5] Dong A Univ, Coll Med, Dept Internal Med, Div Infect Dis, Pusan, South Korea

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 11期

关键词：

PHARMACOKINETICS; PLASMA; TRIAL;

D O I：

10.1128/AAC.04035-14

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.

引用

页码：6993 / 6995

页数：3